Clover Health (CLOV) shares Q4 2025 supplemental shareholder Q&A in new 8-K

Rhea-AI Filing Summary

Clover Health Investments, Corp. furnished an update to investors by publishing written responses to a selection of frequently asked supplemental questions related to its fourth quarter 2025 earnings announcement. The company aims to further engage its shareholder base through this additional Q&A material.

The supplemental shareholder questions and answers are included as Exhibit 99.1 to this report and are also available in the investor relations section of the company’s website. This information is furnished under Regulation FD and is not deemed filed for liability purposes under the Exchange Act.

FALSE0001801170CLOVER HEALTH INVESTMENTS, CORP. /DE00018011702026-03-062026-03-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 6, 2026

CLOVER HEALTH INVESTMENTS, CORP.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39252			98-1515192
(State or Other Jurisdiction			(Commission File Number)			(IRS Employer
of Incorporation)						Identification No.)

Address Not Applicable(1)			Address Not Applicable(1)
(Address of Principal Executive Offices)			(Zip Code)

Not Applicable(1)

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Trading

Title of each class

Symbol(s)

Name of each exchange on which registered

Class A Common Stock, par value $0.0001 per share

CLOV

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

(1) We are a remote-first company. Accordingly, we do not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, stockholder communications required to be sent to our principal executive offices may be directed to the email address: secretary@cloverhealth.com, or to our agent for service of process at The Corporation Trust Company, 1209 Orange Street, Wilmington, Delaware 19801.

Item 7.01. Regulation FD Disclosure.

On March 6, 2026, Clover Health Investments, Corp. (the “Company”) published a list of responses to a selection of frequently asked supplemental questions submitted in connection with the Company's fourth quarter 2025 earnings announcement in order to further engagement with the Company's shareholder base. The supplemental questions and the Company's accompanying written responses are furnished as Exhibit 99.1 to this Current Report on Form 8-K, and are also available on the investor relations section of the Company's website.

The information set forth in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed to be incorporated by reference into any filing made under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) List of Exhibits

Exhibit No.			Description
99.1			Supplemental Shareholder Q&A dated March 6, 2026
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Clover Health Investments, Corp.

Date:

March 6, 2026

By:

/s/ Peter Kuipers

Name:

Peter Kuipers

Title:

Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

FAQ

What did Clover Health (CLOV) disclose in its latest 8-K filing?

Clover Health disclosed that it published written responses to frequently asked supplemental questions related to its fourth quarter 2025 earnings announcement. These responses are meant to enhance engagement with shareholders and are furnished as Exhibit 99.1 and posted on its investor relations website.

What is Exhibit 99.1 in Clover Health (CLOV)’s March 6, 2026 8-K?

Exhibit 99.1 is a supplemental shareholder Q&A dated March 6, 2026. It contains Clover Health’s written responses to a selection of frequently asked supplemental questions submitted in connection with the company’s fourth quarter 2025 earnings announcement, supporting additional communication with investors.

Is Clover Health’s supplemental Q&A in the 8-K considered filed under the Exchange Act?

No, the supplemental Q&A information in Item 7.01, including Exhibit 99.1, is furnished rather than filed for purposes of Section 18 of the Exchange Act. It is also not incorporated by reference into other Securities Act or Exchange Act filings unless specifically referenced.

Where can investors access Clover Health (CLOV)’s supplemental shareholder Q&A?

Investors can access the supplemental shareholder Q&A as Exhibit 99.1 to the March 6, 2026 report and on the investor relations section of Clover Health’s website. The Q&A addresses selected supplemental questions tied to the company’s fourth quarter 2025 earnings announcement.

Why did Clover Health (CLOV) issue a supplemental shareholder Q&A on March 6, 2026?

Clover Health issued the supplemental shareholder Q&A to respond to frequently asked supplemental questions received after its fourth quarter 2025 earnings announcement. The goal is to further engage with the existing shareholder base by providing additional written clarifications and explanations beyond the original earnings materials.

Who signed Clover Health (CLOV)’s March 6, 2026 8-K related to the supplemental Q&A?

The March 6, 2026 report was signed on behalf of Clover Health Investments, Corp. by Peter Kuipers. He is identified as the company’s Chief Financial Officer, serving as both the principal financial officer and principal accounting officer for purposes of the signature requirement.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.7 KB